What is Pepticom?
Pepticom is at the forefront of pharmaceutical innovation, designing novel peptide drug candidates through advanced biocomputational AI software. Their proprietary platform is engineered to optimize the drug discovery process, thereby reducing development risks and costs while accelerating time to market. By leveraging AI for superior binding peptide identification and designing drug candidates across various chemical structures, Pepticom aims to revolutionize 21st-century medicine and enhance the availability of peptide therapeutics through strategic collaborations and in-house development.
How much funding has Pepticom raised?
Pepticom has raised a total of $14.2M across 3 funding rounds:
Series A
$5M
Other Financing Round
$2.6M
Series A
$6.6M
Series A (2019): $5M with participation from Chartered Group
Other Financing Round (2021): $2.6M led by The Chartered Group
Series A (2025): $6.6M supported by Japan Israel High Tech Ventures 2 LP
Key Investors in Pepticom
Japan Israel High Tech Ventures 2 LP
Japan Israel High Tech Ventures 2 LP is an investment firm that likely focuses on technology and innovation, given its name and participation in a significant funding round.
Chartered Group
Chartered Group is an entity that has provided backing to Pepticom, indicating a strategic interest in the company's drug discovery and development initiatives.
The Chartered Group
The Chartered Group, operating with the domain charteredgroup.com, has participated in Pepticom's financing rounds, suggesting a role in supporting the company's growth and technological advancements in the biopharmaceutical sector.
What's next for Pepticom?
With a recent major strategic investment and substantial total funding, Pepticom is well-positioned for its next phase of growth. This capital infusion is anticipated to fuel further development of their AI-driven discovery platform, expand their pipeline of peptide drug candidates, and potentially forge new strategic partnerships. The company's focus on reducing development risks and costs, coupled with its mission to improve access to novel therapeutics, suggests a trajectory aimed at significant market penetration and clinical advancement.
See full Pepticom company page
